Aurinia Pharmaceuticals Balance Sheet
NASDAQ: AUPHHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aurinia Pharmaceuticals financial position
At the end of fiscal 2025, Aurinia Pharmaceuticals reported total assets of $751.6 million, up 36.5% from a year earlier against total liabilities of $170.3 million. Shareholders' equity stood at $581.3 million, or 77.3% of assets. The company held $80.2 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 5.25, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Aurinia Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 80.16M | 83.40M | 48.76M | 94.09M | 231.64M | 272.35M | 306.02M | 117.97M | 165.63M | 39.65M |
| Short-Term Investments | — | — | — | — | — | — | 0 | 7.89M | 7.83M | 0 |
| Inventory | 45.69M | 39.23M | 39.70M | 24.75M | 19.33M | 13.93M | 0 | — | — | — |
| Total Current Assets | 491.97M | 446.60M | 424.80M | 442.54M | 513.32M | 419.43M | 315.14M | 132.85M | 175.25M | 41.42M |
| Property, Plant & Equipment | 2.11M | 2.73M | 3.35M | 3.65M | 4.42M | 4.79M | 93.00K | 41.00K | 31.00K | 29.00K |
| Intangible Assets | 3.76M | 4.36M | 4.98M | 6.42M | 8.40M | 9.33M | 8.86M | 12.62M | 14.12M | 15.55M |
| Total Assets | 751.59M | 550.64M | 548.06M | 470.86M | 543.37M | 463.66M | 324.30M | 145.86M | 189.85M | 57.00M |
| Accounts Payable | 3.31M | 5.19M | 4.33M | 3.09M | 3.88M | 2.63M | 4.15M | 7.07M | 7.96M | 5.79M |
| Total Current Liabilities | 93.72M | 97.76M | 77.19M | 46.11M | 40.65M | 32.00M | 11.29M | 7.26M | 8.15M | 7.93M |
| Total Liabilities | 170.26M | 173.17M | 170.11M | 65.42M | 64.28M | 55.91M | 25.70M | 33.29M | 24.10M | 21.05M |
| Shareholders' Equity | 581.33M | 377.48M | 377.95M | 405.44M | 479.09M | 407.75M | 298.60M | 135.72M | 177.92M | 35.95M |
| Retained Earnings | -649.37M | -936.57M | -942.32M | -864.30M | -756.12M | -575.16M | -472.48M | -415.96M | -351.84M | -281.05M |
| Net Cash (Debt) | 80.16M | 83.40M | 48.76M | 94.09M | 231.64M | 272.35M | 306.02M | 125.86M | 173.46M | 39.65M |
| Shares Outstanding | 132.32M | 140.88M | 143.83M | 142.27M | 141.60M | 126.70M | 111.80M | 85.50M | — | — |
This table shows 10 annual periods of Aurinia Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, short-term investments, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow AUPH's reporting calendar. What is a balance sheet?